Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs—Part B: Prostate and Urinary Tract Tumors
George J. Netto, Mahul B. Amin, Daniel M. Berney, et al.
European Urology (2022) Vol. 82, Iss. 5, pp. 469-482
Closed Access | Times Cited: 177

Showing 76-100 of 177 citing articles:

Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers
Pedro C. Barata, Kevin Zarrabi, Axel Bex, et al.
European Urology (2024)
Closed Access | Times Cited: 1
Clinical impact of a subtype of urothelial carcinoma in nonmuscle-invasive bladder cancer
Akinori Minato, Michiko Yoshii, Shiro Watanabe, et al.
Japanese Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 1
Update on classification of oncocytic neoplasms of the kidney
André Oszwald, Gabriel Wasinger, Lucia Zisser, et al.
Current Opinion in Urology (2023) Vol. 33, Iss. 3, pp. 239-244
Closed Access | Times Cited: 4
Efficacy and safety of transurethral resection of bladder tumour combined with chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1 high-grade or T2 bladder cancer: a protocol for a randomized controlled trial
Xiangwei Yang, Shiqiang Zhang, Yajiao Cui, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 4
SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)
María José Méndez-Vidal, Martín Lázaro Quintela, Nuria Lainez-Milagro, et al.
Clinical & Translational Oncology (2023) Vol. 25, Iss. 9, pp. 2732-2748
Open Access | Times Cited: 4
Clear Cell Adenocarcinoma of Urethra: Clinical and Pathologic Implications and Characterization of Molecular Aberrations
Boram Song, Seok Hyun Lee, Jeong Hwan Park, et al.
Cancer Research and Treatment (2023) Vol. 56, Iss. 1, pp. 280-293
Open Access | Times Cited: 4
Recent insights on the clinical, pathological, and molecular features of intraductal carcinoma of the prostate
Yushi Naito, Masashi Kato, Jun Nagayama, et al.
International Journal of Urology (2023) Vol. 31, Iss. 1, pp. 7-16
Open Access | Times Cited: 4
Predicting Preoperative Pathologic Grades of Bladder Cancer Using Intravoxel Incoherent Motion and Amide Proton Transfer-Weighted Imaging
Ling‐Yu Chang, Xinghua Xu, Guangtai Wu, et al.
Academic Radiology (2023) Vol. 31, Iss. 4, pp. 1438-1446
Closed Access | Times Cited: 4
Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review
Satoru Taguchi, Taketo Kawai, Tohru Nakagawa, et al.
Japanese Journal of Clinical Oncology (2023) Vol. 54, Iss. 3, pp. 254-264
Closed Access | Times Cited: 4
Tumors of the Urinary System and Male Genital Organs: 2022 World Health Organization Classification and Multidisciplinarity
Rodolfo Montironi, Alessia Cimadamore
European Urology (2022) Vol. 82, Iss. 5, pp. 483-486
Closed Access | Times Cited: 7
International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members
Irene Beijert, Liang Cheng, Fredrik Liedberg, et al.
European Urology Open Science (2023) Vol. 52, pp. 154-165
Open Access | Times Cited: 3
The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment
Aziz Hakkı Civriz, Kerem Teke, Enes Malik Akdaş, et al.
Urologic Oncology Seminars and Original Investigations (2023) Vol. 41, Iss. 12, pp. 486.e1-486.e13
Closed Access | Times Cited: 3
Aberrant expression of GATA3 in metastatic adenocarcinoma of the prostate: an important pitfall
João Lobo, Nazario Pio Tenace, Sofía Cañete‐Portillo, et al.
Histopathology (2023) Vol. 84, Iss. 3, pp. 507-514
Open Access | Times Cited: 3
The influence of the initial clinical presentation of upper tract urothelial carcinoma on histopathological tumor features
Dora Jakus, Ivana Šolić, Josip A. Borovac, et al.
International Urology and Nephrology (2023) Vol. 56, Iss. 4, pp. 1335-1341
Closed Access | Times Cited: 3
Contemporary sex-specific analysis of the association of marital status with cancer-specific mortality in primary urethral carcinoma patients
Simone Morra, Lukas Scheipner, Andrea Baudo, et al.
Urologic Oncology Seminars and Original Investigations (2023) Vol. 42, Iss. 2, pp. 31.e1-31.e8
Closed Access | Times Cited: 3
Challenges and opportunities in the management of non-urothelial bladder cancers
Jacqueline T. Brown, Vikram M. Narayan, Shreyas Joshi, et al.
Cancer Treatment and Research Communications (2022) Vol. 34, pp. 100663-100663
Open Access | Times Cited: 5
GATA3 expression in clear cell adenocarcinoma of the lower urinary tract: a potential diagnostic pitfall
Mahmut Akgul, Robert Humble, Abdullah Ösme, et al.
Diagnostic Pathology (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 4
UROSCAN and UROSCANSEQ: a large-scale multicenter effort towards translation of molecular bladder cancer subtypes into clinical practice – from biobank to RNA-sequencing in real time
Fredrik Liedberg, Johan Abrahamsson, Carina Bernardo, et al.
Scandinavian Journal of Urology (2022) Vol. 57, Iss. 1-6, pp. 2-9
Open Access | Times Cited: 4
Development and validation of a prognostic nomogram for overall and disease-specific survival in patients with sarcomatoid urothelial carcinoma
Leonidas Nikolaos Diamantopoulos, Dimitrios Makrakis, Dimitrios Korentzelos, et al.
Urologic Oncology Seminars and Original Investigations (2023) Vol. 41, Iss. 6, pp. 296.e17-296.e28
Closed Access | Times Cited: 2
Clinical Presentation and Targeted Interventions in Urachal Adenocarcinoma: A Single-Institution Case Series and Review of Emerging Therapies
Akshay Mathavan, Akash Mathavan, Rodrigo Murillo-Alvarez, et al.
Clinical Genitourinary Cancer (2023) Vol. 22, Iss. 1, pp. 67-75
Closed Access | Times Cited: 2
Demographics, Clinical Characteristics and Survival Outcomes of Primary Urinary Tract Malignant Melanoma Patients: A Population-Based Analysis
Simone Morra, Reha‐Baris Incesu, Lukas Scheipner, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4498-4498
Open Access | Times Cited: 2
The utilization of single-cell sequencing technology in investigating the immune microenvironment of ccRCC
Yuanxin Liu, Guangzhen Wu
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 2
Editorial for “Association of Pathological Features and Multiparametric MRI‐Based Radiomics with TP53‐Mutated Prostate Cancer”
Satoru Takahashi
Journal of Magnetic Resonance Imaging (2024) Vol. 60, Iss. 3, pp. 1146-1147
Closed Access
Preoperative Systemic Inflammation Score Predicts the Prognosis of Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy
Qihao Wang, Jianjun Ye, Zeyu Chen, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 3, pp. 791-791
Open Access
Mixed-Grade Urothelial Carcinoma: Insights Into Clinical Behavior and Prognostic Implications Compared to Pure Low-Grade and High-Grade Urothelial Carcinomas
Fateme Khalatbari, Miremad Moafi-Madani, Ali Amin
Archives of Pathology & Laboratory Medicine (2024) Vol. 148, Iss. 12, pp. 1352-1357
Open Access

Scroll to top